Top

Fellowship Details & Requirements

A group of infectious diseases fellows posing for a photo

In 1974 Herbert L DuPont, M.D., chair of Infectious Diseases at McGovern Medical School (then known as the UTHealth Science Center at Houston Medical School) and Gerald P Bodey, M.D., chair for Infectious Diseases at MD Anderson, agreed to start a combined ID fellowship program that offered rotations at clinics affiliated with MD Anderson, Memorial Hermann Hospital and McGovern Medical School. Two tracks were offered, the traditional track and the immunocompromised track. Fellows in the immunocompromised track spent most of the time at MD Anderson and rotated in the general ID service at McGregor Medical School.

In 1990, the program expanded to include rotations at the Lyndon B Johnson General Hospital. By 2005, a similar agreement with Baylor College of Medicine was established, offering training in both the traditional and immunocompromised tracks. In 2019, MD Anderson launched a nonstandard training (NST) program with UTHSC in Transplant and Oncology with approval of the Texas Medical Board. A few years later in 2024, fellows in the MD Anderson NST program began rotating in the immunocompromised service at The Houston Methodist Hospital, which offers exposure to many patients undergoing solid organ transplantation.

MD Anderson is the largest comprehensive cancer center in the country and is located in the largest medical center in the world (Texas Medical Center). Fellows rotating at MD Anderson acquire ample clinical experience rotating in the difference consult services and pursue research training opportunities in infectious diseases following ACGME requirements. Our clinical and basic science faculty provide clinical and research support and have successfully mentored trainees that are now full-time clinicians, clinician investigators, clinician educators or physician scientists.

Eligibility, Prerequisites & Application Process

Infectious Diseases fellows are invited for interviews by applying to one of our joint programs. Prospect applicants can also review our Graduate Medical Education office requirements.

Program Goals & Objectives

Our combined Infectious Diseases fellowship program have the following goals and objectives aligned to the six core ACGME competencies:

Medical Knowledge:

Acquire proficiency and expertise in the recognition, diagnosis, and management of common and unusual infectious diseases in immunocompromised and cancer patients
Recognize and manage infectious and non-infectious complications associated with commonly used immunosuppressive drugs, chemotherapeutic agents, targeted therapies and adoptive cellular therapies
Understand the current cancer treatment modalities that have implications in the increased risk, diagnosis and management of infectious diseases
Develop proficiency in the interpretation of antimicrobial susceptibility testing and molecular based diagnosis of infectious agents
Appropriate use of antimicrobial agents according to antimicrobial stewardship guidance. Understand the importance of proper dosing and recognize and manage antimicrobial related toxicities
Recognize and apply strategies for prevention of infections, including antimicrobial prophylaxis indications, timing and duration

Patient care:

Conduct thorough medical histories and physical exams focused on infectious diseases
Develop comprehensive diagnostic and therapeutic management plans
Recognize and treat infectious complications in cancer patients across various stages of care
Effectively order and interpret relevant diagnostic tests

Interpersonal and communication skills:

Learn and refine how to communicate sensitively and effectively with patients and families of cancer patients with infectious diseases
Demonstrate cooperative team building with all members of the consulting team including nurses, coordinators, data managers and physicians/surgeons

Professionalism:

Interact professionally towards patients, families, colleagues and all members of the health care team
Acquire the ability to display an appreciation of the social context of illness

Practice base learning:

Refine the management of infections, and recognize medical, social, and ethical limitations of cancer patients in the oncology and the palliative care service
Describe and demonstrate knowledge of fundamental resources including the AST transplant ID guidelines, evidence-based medicine databases and additional guidelines from other critical sources
Demonstration of these resources directly in patient care and in case-based discussions with transplant ID faculty

Improvement and systems-based practice:

Acquire and improve skills in critical analysis of clinical literature and conducting research
Expected to work with the service requesting the consultation to assure that care for the patient’s medical needs is properly coordinated with care being delivered by the primary service
Expected to integrate knowledge learned through participation in ward rounds, teaching conferences and other educational activities into their practice
Consider the cost-effectiveness of diagnostic, prevention and treatment strategies when selecting such strategies for patients, particularly as it relates to exercising antibiotic stewardship
Refine strategies for prevention of infections and infection control measures in this cancer population

Program Structure & Curriculum

Program duration: Two years

Patient care requirement: At least 12 months to fulfil the educational requirements of the American Board of Internal Medicine

Introductory month: Introductory lectures at the Microbiology laboratory and Antimicrobial Stewardship

Clinical rotations:
Four-week rotations at MD Anderson and across affiliated hospitals at UTHSC and BCM. Fellows spend at least a month in each one of our consult teams, consisting of 1-2 fellows, 1-2 Advanced Practice providers, 1 ID clinical pharmacist and an ID faculty attending.

The Infectious Diseases Consultation services are:

ID Hospital Medicine
ID Surgical Oncology
ID Leukemia
ID Stem cell Transplant
ID Lymphoma, myeloma, and targeted cellular therapy

Fellows are responsible for evaluating all patients on the Consult service. Fellows have the opportunity to select elective rotations in the second year of fellowship.

Clinical conferences:
All fellows actively participate and attend department and shared clinical conferences:

Tuesday 12:30 p.m.: journal club session, research presentation session
Wednesday 8 a.m. ID clinical conference: ID department conference where clinical cases are presented by fellows and discussed with all faculty, ID pharmacists, APPs and clinical microbiologists
Wednesday 12 p.m. Texas Medical Center ID City Wide Conference: Presentation of most interesting cases from all hospital facilities followed by a rich educational wide group discussion
Thursday 1 p.m. ID Core Curriculum conference: ID board-oriented conference

Outpatient clinic rotations:
Fellows participate in continuity clinics at the respective programs and may also choose to rotate in our General ID, Transplant ID and Hepatitis outpatient clinics.

Research:

Fellows select their research mentor during the first year of fellowship
Fellows have 6-12 months of research experience which can be tailored to personal goals and objectives
All fellows present their research in national and international Infectious Diseases society meetings and publish in peer reviewed journals

Supervision and Evaluation:
Supervision:

All fellows are under direct supervision of attending faculty.
The program has a progressive and incremental increase in patient care responsibilities as the fellow demonstrates the skills outlined in the competency-based goals and objectives.

Evaluation:

Fellows are evaluated at the end of each clinical rotation by attending faculty according to the ACGME 6 core competencies.
Biannual evaluations by the clinical competence committee.
Periodical meetings with program director and research mentor to discuss progress and career and research goals.

On-call duties:

Weekdays, after-hours: All rotating fellows expected to attend calls at home if paged by consulting team.
Weekend call: All rotating fellows alternate in-hospital weekend calls.
Other Educational Opportunities: Participation in Quality Improvement, Antimicrobial Stewardship and Infection Control programs according to career goals.

Program Faculty & Leadership

Infectious Diseases Faculty

David Tweardy, M.D., Professor and Head of Division of Internal Medicine

Dr. Tweardy is a graduate from Case Western Reserve University Infectious Diseases Fellowship program. His overall research interests focus on understanding and modulating the host damage response to microbial and other injuries to treat disease. His basic research interests over the past 30 years have centered on cytokines and cytokine signaling. In particular, he has focused on the second messenger— signal transducer and activator of transcription (STAT) 3 — which is critical in the signal transduction pathway of over 40 cytokines. Work by his group and others has shown that STAT3 makes essential contributions to chronic inflammation, fibrosis and cancer. The clinical research interests of Dr. Tweardy are focused on the use of a small-molecule STAT3 inhibitor, TTI-101, identified in his lab to treat and/or prevent chronic inflammation, fibrosis and cancer.

Roy Chemaly, M.D., MPH, CMQ, Professor, Department Chair and Director of the Clinical Virology Research program

Dr. Chemaly is a graduate from the Cleveland Clinic Infectious Diseases Fellowship program. He is a world leading researcher in virology. His interests include studies on epidemiology, severity, prognosis, prevention and treatment of respiratory viral infections in immunocompromised cancer patients and in prevention of health care-associated infections. He is the founder and past chair of the Transplant Infectious Diseases Interest Group of the American Society of Bone Marrow Transplantation. He also is a member of the writing committee of the ASBMT guidelines and the European Committee for infections in Leukemia (ECIL 8); executive member of the council for the International Immunocompromised Host Society (ICHS); and Chair for the working group on respiratory viruses (ESGREV) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).

Pablo C. Okhuysen, M.D., Professor and Fellowship Program Director

Dr. Okhuysen is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program (‘94). The Okhuysen laboratory research interests include the identification, epidemiology, pathogenesis, host immune response, treatment and prevention of gastrointestinal infections, including diarrheagenic Escherichia coli, Cryptosporidium, Clostridioides difficile in immunocompromised and cancer patients. Dr. Okhuysen served on the board of scientific advisors for the CDC and has been an advisor to NASA. He has served on the Infectious Diseases Society of America Publications and Research Awards Committees and was awarded the Oswald Avery Award for Early Achievement by the Infectious Diseases Society of America in 2007. He also is a past director of the NIH NCRR-funded General Clinical Research Center at UTHealth Houston/Memorial Hermann Hospital and co-lead the joint UTHealth Houston McGovern Medical School NIH CTSA-funded Center for Clinical and Translational Services. He has repeatedly received the best teacher award from fellows in the McGovern and BCM fellowship programs.

Eduardo Yepez Guevara, M.D., Assistant Professor and Fellowship Associate Program Director

Dr. Yepez is a graduate from the UTHealth Houston Science Center (UTHSC) McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program with additional advanced training in Transplantation Infectious Diseases at UTHSC. He serves as the associate director of the Antibiotic Stewardship team and is an active member of the Pharmacy and Therapeutics Committee. Dr. Yepez’s research interests are infections in patients with hematological malignancies, including evaluation of reactivation or onset of new infections in cancer and immunocompromised patients exposed to new targeted cancer therapies and immunotherapy; gastrointestinal infections, including Clostridioides difficile infection; and viral hepatitis, including evaluation and treatment, risk of reactivation and safety of antiviral therapy. He also works at the viral hepatitis clinic and collaborates in multiple research projects.

Javier Adachi, M.D., Professor and Clinical Vice-Chair

Dr. Adachi is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program and is a past associate director of the infectious diseases fellowship at MD Anderson Cancer Cener and Baylor College of Medicine. Dr. Adachi is the clinical service director of Infectious Diseases in Leukemia and the director of the division’s quality improvement projects. He is involved in several research projects related to cancer patients. He actively mentors fellows, midlevel providers, nurses and junior Faculty participating in the Clinical Safety and Effectiveness course, a yearly QI (Quality Improvement) training course offered at MD Anderson that enhances training in QI and allows participants to apply for the Certificate in Medical Quality.

Ella Ariza, M.D., Professor

Dr. Ariza is a graduate from the University of Miami’s Jackson Memorial Hospital Infectious Diseases fellowship program, with subsequent third-year training in Transplant Infectious Diseases at the Mayo Clinic in Rochester, Minn. Dr. Ariza is the clinical service director of Infectious Diseases in the Hematopoietic Stem Cell Transplant consult service. Her clinical and research interests include the management of infections in stem cell transplant recipients with an emphasis on viral respiratory and vaccine-preventable infections, as well as patients undergoing CAR-T and other adoptive cellular therapies.

Uddalak Bharadwaj, Ph.D., Assistant Professor

Dr. Bharadwaj is a member of Dr. Tweardy’s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. His overall interest is in the role of IL-6/STAT3, IFN/STAT1/2 signaling in cancer initiation, progression and immune modulation. Dr. Bharadwaj is focused on delineating the exact roles of these pathways, especially a group of Interferon Stimulated Genes, the IFN-related DNA damage resistance signature (IRDS) gene set, in conferring chemo-radio resistance, and metastatic abilities to head and neck squamous cell carcinoma (HNSCC) cells, as well as how the HNSCC-associated viruses, e.g. HPV (human papillomavirus), HCV (hepatitis C virus), modulate the STAT1/3 pathways to affect disease severity in these patients. Also, he is actively involved in preclinical research involving co targeting of STAT3, a known immune modulatory agent.

Anne-Marie Chaftari, M.D., Professor

Dr Chaftari is a graduate from Saint Joseph University, Faculty of Medicine in Beirut, Lebanon. She completed an anesthesia residency program at the American University of Beirut in Lebanon, Internal Medicine Residency training at Staten Island University Hospital, in Staten Island, N.Y., a fellowship in Geriatrics at Tulane University Medical and postdoctoral training on Infectious Diseases at MD Anderson. She oversees the daily operation of Dr. Issam Raad’s clinical research team and the conduct of clinical studies. She leads several clinical research trials at the institution and collaborates in multiple multicenter
clinical research projects sponsored by industry and NIH. Her clinical research areas of interest include infectious diseases complications in cancer patients, such as central line-associated bloodstream infections, and neutropenic fever. Other areas of interest include novel antimicrobial therapies and biomarkers of
sepsis.

Natalie Janine Dailey Garnes, M.D., MPH, MS, Associate Professor

Dr. Garnes is a graduate from the Baylor College of Medicine Infectious Diseases Fellowship Program. Dr. Garnes is dually boarded in adult and pediatric infectious diseases. She is the clinical service director for the pediatric infectious diseases consult service, director of the outpatient parenteral antimicrobial therapy program and director of the Antimicrobial Stewardship Program. Her research interests include infections in pediatric immunocompromised and cancer patients.

Bruno P. Granwehr, M.D., Professor

Dr. Granwehr is a graduate from The University of Texas Medical Branch Infectious Diseases Fellowship program. He previously has served as site director and associate director of the MD Anderson UTHSC and BCM Infectious Diseases combined fellowship programs. He is the clinical director of the Infectious Diseases Hospital Medicine consult service. His research interests include the early identification of HIV in patients with newly diagnosed cancer and the oncologic complications of HIV. Dr. Granwehr is also interested in the management of HIV and hepatitis C infection in patients receiving cancer chemotherapy. Dr. Granwehr received the 2017-18 Best Infectious Diseases Fellowship Teacher Award from the BCM fellows.

Ray Hachem, M.D., Professor

Dr. Ray Hachem is director of the Infectious Disease Training & Observership program in the Department of Infectious Diseases, Infection Control & Employee Health at MD Anderson. His research interests focus on pathophysiology and management of diseases in humans caused by bacterial and fungal pathogens. He has been involved in conducting many clinical trials, as well as basic and translational research that pave the way to multiple studies to improve the care of cancer patients with infections. He has worked extensively on clinical trials pertaining to invasive fungal infections and device related infections. He has been involved in over 20 clinical trials or laboratory studies, including several animal models. Dr. Hachem served as the chairman of the Division of Internal Medicine Research Committee. He also serves on the Institutional Review Board, the Institutional Research Grant (IRG) Committee, and the Ad Hoc Committee of the Infection Control Committee for the Prevention of Fungal Infections.

Teny M. John, M.B.B.S., M.D., Assistant Professor

Dr. John is a graduate from the Cleveland Clinic Internal Medicine and Infectious Diseases Fellowship Program. His clinical expertise lies in mycology, emphasizing diagnostics, therapeutics, and stewardship. Dr. John holds the position of chair at the department's pivotal Wednesday clinical conference. His research focuses on mycology and breath metabolomics. He actively contributes as a member of the "Young MSG" within the Mycosis Study Group, the consortium for clinical metagenomics in infectious diseases and serves on the ID Metabolites/Direct MALDI Work group for the American Society of Transplantation Biomarker Consensus Conference.

Moses Kasembeli, Ph.D., Assistant Professor

Dr. Kasembeli is a member of Dr. Tweardy’s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. Dr. Kasembeli’s research is centered on the development of potent and selective inhibitors of STAT3 activity to target cancer and diseases marked by chronic inflammation. He also studies molecular mechanisms of a rare primary immune deficiency syndrome linked to loss of function of STAT3. He is primarily interested in the modulation of the activity of STAT3 with the goal of reducing its activity in diseases in which it is hyper-activated, such as cancer, and enhance its activity in diseases marked by loss of function of STAT3, such as autosomal dominant hyper IgE syndrome (AD-HIES).

Fareed Khawaja, M.D., Associate Professor

Dr. Khawaja completed his Internal Medicine and Infectious Diseases training at McGovern Medical School UTHealth Science Center at MD Anderson. His research scope is clinical studies focused on viral infections in patients with hematologic malignancies and recipients of cellular therapy. He leads multiple
interventional trials to treat and prevent CMV and respiratory viral infections (including COVID-19). In addition, he heads multiple database studies to measure infectious complications in recipients of novel therapies for hematologic malignancies, such as CAR (Chimeric Antigen Receptor) T cell therapy.

Dimitrios P Kontoyiannis, M.D., Sc.D., Professor

Dr. Kontoyiannis is the Robert Hickey Endowed Chair, a professor in Infectious Diseases, and the deputy head of research in the Division of Internal Medicine. Dr. Kontoyiannis is a graduate from Massachusetts General Hospital’s Harvard Medical School Infectious Diseases Fellowship program. He is a leading world researcher in mycology, studying the pathogenesis of invasive fungal infections (IFIs) and the development of novel therapeutic strategies against these devastating infections. Other areas of interest include antifungal resistance, novel diagnostics, delivery systems and fungal pharmacology. For more than 25 years, the Kontoyiannis laboratory and clinical research program has made significant contributions to broaden our understanding and knowledge of IFIs, the immunopathology of IFIs, activity of conventional and novel antifungal compounds and combination therapy, including development of novel experimental Drosophila and mice models. Dr. Kontoyiannis has been member of the writing committee for aspergillus treatment guidelines for Infectious Diseases Society Of America and the chair of the treatment guidelines for aspergillosis and rare molds for American Society of Transplantation and Cellular Therapy, president-elect of the Mycoses Study Group (2024-2026), past president of the International Immunocompromised Host Society and leader of the European Confederation for Medical Mycology (ECMM) Diamond Excellence in Mycology Center at MD Anderson. He is a recipient of many national and international prestigious awards for his research in mycology and a member of honorific societies such as Association of American Physicians, American Medical Association and American Association for the Advancement of Science.

Victor E. Mulanovich, M.D., Professor

Dr. Mulanovich has served as Infectious Diseases department chair ad interim, past clinical vicechair. Dr. Mulanovich is a graduate from the University of Alabama at Birmingham Infectious Diseases Fellowship Program. He conducts research in immunocompromised and cancer patients. His clinical research interests include infections in patients with hematologic malignancies and in recipients of hematopoietic stem cell transplants. He was Director of the Antimicrobial Stewardship Program. In multiple occasions, he received the outstanding teaching award in Infectious Diseases by UTHSC and BCM.

Issam I. Raad, M.D., Professor

Dr. Raad has previously served as department chair of Infectious Diseases. He is a graduate from the University of Florida Infectious Diseases fellowship program. Dr. Raad is considered one of the world’s leading experts in health care-related infections and infections in cancer. His research includes development of innovative antimicrobial central venous catheters and devices that have reduced the risk of bloodstream infections worldwide by more than 12-fold. In the most recent CDC Guidelines (2011), his innovations (including the antimicrobial catheters and maximal sterile barrier) have been recommended at the highest level (Category 1A) for the prevention of health care associated bloodstream infections, which have become the standard of care. He has expanded his research to develop other antimicrobial coated devices, including urologic and breast implants, ventriculostomy and drainage catheters. He has been awarded as distinguished educator at MD Anderson in 2019 and The Society for Healthcare Epidemiology of America’s Mentor Scholar award in 2015.

Prema Robinson, Ph.D., Associate Professor

Dr. Robinson is a member of Dr. Tweardy’s Laboratory, which focuses on understanding and modulating the host damage response to microbial and traumatic injury to treat disease. Dr. Robinson is actively involved in studying the role of substance P, a pro-inflammatory neuropeptide and pain transmitter in various cancers, including inflammation-associated colon cancer and triple negative breast cancer.

Samuel Shelburne, M.D., Ph.D., Professor

Dr. Shelburne is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program. Dr. Shelburne is the deputy chair for scholarly activity in the department, director for the Genomic Infectious Diseases research group at MD Anderson, leading member for the steering committees for antibiotic resistance, Gulf Coast Consortium on Antimicrobial Resistance and Microbiome working groups. He is also a member of the Antimicrobial Resistance Peer Reviewed Medical research program,
a medical research program at the U.S. Department of Defense directed by
Congress. His research team focuses on understanding the molecular basis
of bacterial infections in humans and the molecular basis underlying bacterial
antimicrobial resistance (AMR). Dr. Shelburne is the head of the immunocompromised section of the NIH Funded Antibiotic Resistance Leadership Group and has published on AMR mechanisms in bacteria ranging from Staphylococcus epidermidis to Escherichia coli. The Shelburne laboratory seeks to understand how variation in bacterial virulence impacts clinical outcomes, using group A streptococcus (GAS) as a model organism. Specific projects include unraveling the complex regulation of virulence by the two-component regulatory system CovRS in GAS, identifying mechanisms driving emergence of new GAS clones, and understanding how resistance to oxidative stress impacts disease occurrence. He also received the outstanding clinical research mentor at MD Anderson School of Health Professions in 2019.

Amy Spallone, M.D., Assistant Professor and Chief Infection Control Officer

Dr. Spallone is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program. Dr. Spallone is the chief infection control officer at MD Anderson and our department's patient quality safety officer. Dr. Spallone’s research interests include emerging pathogens, viral infections, and infection control measures in immunocompromised populations. Under the mentorship of Dr. Roy Chemaly, Dr. Spallone assists in several clinical trials, including investigational antiviral agents for respiratory viral pathogens and mapping changes in the respiratory microbiome/virome composition to predict clinical outcomes in hematopoietic cell transplantation recipients and patients with leukemia. She is the primary investigator on environmental surface disinfection studies piloting hand-held UV devices and a co-mentor/collaborator with Dr. Sam Shelburne on utilizing Oxford Nanopore Technology third generation sequencing for rapid identification of hospital-acquired infections in health care settings.

Krithika Srinivasan, M.D., Assistant Professor

Dr. Srinivasan is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program, and she also completed a secondary fellowship in Hospital Epidemiology and Infection Control at Stanford University Infectious Diseases and Geographic Medicine Fellowship Program. She is the medical director of Employee Health at MD Anderson. Her interests include the mitigation of biohazards, infection prevention and occupational health in higher education and research institutions.

Ariel Szvalb, M.D., Associate Professor

Dr. Szvalb is a graduate from the Baylor College of Medicine/MD Anderson Infectious Diseases Fellowship Program and past member of Faculty Senate and Pharmacy and Therapeutic Committee. Dr. Szvalb is also a member of Dr. Kontoyiannis clinical research group. His research interests include Pneumocystis jirovecii pneumonia, invasive fungal infections, and device-related infections such as percutaneous nephrostomy tubes, Foley catheters, and Ommaya reservoirs.

Harrys Torres, M.D., Professor

Dr. Torres is an Ashbel Smith Distinguished Professor and Adjunct Professor at the Department of Gastroenterology, Hepatology, and Nutrition. Dr. Torres is a graduate from the UTHealth Houston Science Center McGovern Medical School/MD Anderson Infectious Diseases Fellowship Program. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the U.S., and likely in the world, devoted to managing HCV in cancer patients. He is a member of numerous national committees for professional societies such as American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases. He is the Chair of the AASLD Special Interest Group on HCV. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation. His work addressed the fact that HCV is a neglected condition in cancer patients. Additionally, he has discovered new associations between HCV and other cancers (e.g., Head and Neck cancers). He has also documented the effectiveness, benefits and safety of antiviral therapy in HCV-infected patients with cancer including those with hepatocellular carcinoma and B-cell non-Hodgkin lymphoma. He is the principal investigator for research grants on HCV received from the NIH/NCI and pharmaceutical companies (investigator-initiated studies). Dr. Torres lectures widely nationally and internationally on viral hepatitis in cancer patients. Dr. Torres' work has significantly impacted the standard of care for HCV-infected cancer patients.

George M. Viola, M.D., MPH, Professor

Dr. Viola is a graduate from the Baylor College of Medicine Infectious Diseases Fellowship Program. Dr. Viola is the director of the outpatient clinic and the Solid Cancer and Surgical Related Infectious Diseases services. His main research interests are the prevention, diagnosis and treatment of medical device-related infections in immunocompromised and cancer patients, such as: cardiac implantable electronic device, intravenous catheters, breast tissue expanders after mastectomy, nephrostomy tubes and Ommaya reservoirs.

Sebastian Wurster, M.D., Assistant Professor

A member of Dr. Kontoyiannis’ lab, Dr. Wurster’s research interests are the immunopathology and immunotherapy of fungal infections, innovative mammalian models and mini-host models of invasive mycoses, and translational research as it relates to the diagnosis and treatment of fungal infections. Specifically, he is studying immune checkpoint inhibitors and other immune therapeutics as experimental treatments in murine models of invasive mold infections. Furthermore, he has been a driving force in the development of a high-throughput larval zebrafish model to study interactions of pathogenic fungi with epithelial barriers. He has also developed automated image analysis algorithms to dissect the morphogenesis and proliferation of molds during antifungal (combination) therapy and immune cell encounters. Dr. Wurster has been the recipient of the Division of Internal Medicine Research & Quality Improvement Award 2020 and Cyrus Scholar Award 2021.

Support Staff:

Ms. Lauren Sutton. Program Manager. LMSutton1@mdanderson.org
Ms. Gabrielle E King. Program Coordinator. geking1@mdanderson.org

Clinical Microbiology Department

three people in a clinical microbiology lab looking at a specimen

From left to right: Brenda Snider, clinical microbiology lab coordinator; Kenya Ellis, laboratory supervisor; and Micah Bhatti, M.D., Ph.D., assistant professor, Laboratory Medicine

MD Anderson is supported by a state-of-the-art diagnostic clinical microbiology laboratory, led by Dr. Jeffrey Tarrand, Dr. Xiang-Yang Han, and Dr. Micah Bhatti. This advanced laboratory provides comprehensive services for the identification and isolation of viral, bacterial, fungal, and protozoan parasites. The laboratory uses innovative technologies, including multiplexed nucleic acid amplification tests for syndromic diagnosis, real time antimicrobial susceptibility testing using accelerate pheno® and identification of pathogens using matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOFF MS). Quantitative PCR for common viral agents is performed on site.

During the month of July, first year fellows rotate in the clinical microbiology lab.

Infectious Diseases Clinical Pharmacy Specialists

From left to right: Kevin Lin, Pharm.D., Alex Stabler, Pharm.D., Jovan Borjan, Pharm.D., Nancy Vuong, Pharm.D., Joshua Hendrickson, Pharm.D., Kelsey Olson, Pharm.D., and Meghan Kamath, Pharm.D.

The Infectious Diseases (ID) clinical pharmacists are integral members of the ID team at MD Anderson. They play a crucial role in the daily clinical management of patients with infectious diseases and contribute significantly to antimicrobial stewardship efforts.

Key Responsibilities:

Clinical Support: Provide expert guidance on the management of infectious diseases.

Antimicrobial Stewardship: Review positive blood cultures, HIV cases, and restricted antimicrobial orders, assist with outpatient parenteral antimicrobial therapy and monitor antimicrobial use across the institution.

Collaboration: Work closely with ID faculty and fellows to develop and implement research and quality improvement projects aimed at optimizing antimicrobial utilization and reducing inappropriate prescribing.

The ID clinical pharmacists also oversee their own PGY2 Infectious Diseases Clinical Pharmacy Residency Program, fostering the next generation of experts in this vital field.

Infection Control

A collage of photos with individuals wearing masks

The goal of the Infection Control team at MD Anderson is to prevent, detect, monitor and contain potential infectious disease threats to our patients, visitors and staff. Operating under the Chief Safety and Quality Office, the team works in close collaboration with Dr. Amy Spallone, Chief Infection Control Officer.

Key Functions:

Prevention: Implement strategies to prevent infectious diseases transmission and outbreaks
Detection and Monitoring: Continuously monitor and detect potential infectious threats
Containment: Swiftly respond to and contain infectious disease incidents

Collaboration:

Patient Care: Fellows work closely with the Infection Control team while caring for patients.
Research and Quality Improvement: Fellows can opt to engage in research and quality improvement projects, collaborating with Infection Control to enhance patient safety and care standards.

The Gerald P. Bodey, M.D. Infections in the Immunocompromised Host Clinical Elective

We offer a one-month clinical elective rotation for fellows in ACGME-accredited Infectious Diseases Fellowship Programs in the U.S. who would like to gain in-depth clinical experience in the diagnosis and treatment of infections in immunocompromised and cancer patients. Interested fellows can apply by email to Dr. Pablo Okhuysen at PCOKhuysen@mdanderson.org. Programs interested in sending fellows to MD Anderson for this elective require a Letter of Agreement (LOA) with MD Anderson. For details on establishing educational agreements, please contact Lauren Sutton at LMSutton1@mdanderson.org.

U.S. Medical Student and Resident Rotations

One-month clinical electives are available to U.S. medical students and internal medicine residents in ACGME accredited institutions. As with fellowship positions, a LOA is required between institutions. For additional information, contact Gabrielle King at GEKing1@mdanderson.org

International Medical Students, Residents, and Fellows

International visitors can apply to be visiting observers at our institution. For additional information, contact Gabrielle King at GEKing1@mdanderson.org

Trainee Success & Program Outcomes

Our combined fellowship program maintains a 100% board pass rate in the ABIM Infectious Diseases board examination.

All fellows publish an original research paper in a peer reviewed journal, and present a poster, abstract or oral presentation at a national or international Infectious Diseases conference meetings.

Recent graduates include faculty at the following academic institutions

MD Anderson Cancer Center
McGovern Medical School – The University of Texas Health Science Center at Houston
Baylor College of Medicine
Houston Methodist Hospital
University of Texas Southwestern
Moffitt Cancer Center
University of Oklahoma College of Medicine
University of Kansas
LSU-Shreveport
University of South Florida
Marshall University School of Medicine, West Virginia
Washington U, St Louis
Fujita Health University, Japan
University of Arizona
University of Illinois College of Medicine
University of Nebraska
Indiana University School of Medicine
Medical College of Georgia. Augusta University
Emory University
Brown University

Fellow & Faculty Publications

2018

Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM: Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. Oncologist 2018, 23(6):660-669.
Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K et al: Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun 2018, 9(1):5015.
Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K et al: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun 2018, 9(1):3333.
Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA: Universal screening for hepatitis C: A needed approach in patients with haematologic malignancies. J Viral Hepat 2018, 25(9):1102-1104.
Angelidakis G, Sturgis EM, Economides MP, Jiang Y, Torres HA: Chronic hepatitis C virus infection in patients with nonoropharyngeal head and neck cancers. Oral Oncol 2018, 85:103-105.
Ariza-Heredia EJ, Chemaly RF: Update on infection control practices in cancer hospitals. CA Cancer J Clin 2018, 68(5):340-355.
Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VE: Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int 2018, 31(6):639-648.
Azzi JM, Kyvernitakis A, Shah DP, El Haddad L, Mahajan SN, Ghantoji SS, Heredia-Ariza E, Chemaly RF: Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. J Antimicrob Chemother 2018, 73(11):3162-3169.
Batista MV, El Haddad L, Chemaly RF: Paramyxovirus infections in hematopoietic cell transplant recipients. Curr Opin Infect Dis 2018, 31(6):542-552.
Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N et al: A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae. Mol Ther Methods Clin Dev 2018, 9:305-312.
Chaftari AM, Hachem R, Jiang Y, Shah P, Hussain A, Hamal ZA, Yousif A, Jordan M, Michael M, Raad I: Changing Epidemiology of Catheter-Related Bloodstream Infections in Cancer Patients. Infect Control Hosp Epidemiol 2018, 39(6):727-729.
Chemaly RF, Clark TW: Viral therapeutics: where we are and where we are going. Curr Opin Infect Dis 2018, 31(6):512-513.
Dadwal SS, Kontoyiannis DP: Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn 2018, 18(10):845-854.
Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA: Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma 2018, 5:81-86.
Dandachi D, Wilson Dib R, Fernández-Cruz A, Jiang Y, Chaftari AM, Hachem R, Raad I: Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes. Ann Med 2018, 50(8):713-720.
DebRoy S, Li X, Kalia A, Galloway-Pena J, Shah BJ, Fowler VG, Flores AR, Shelburne SA: Identification of a chimeric emm gene and novel emm pattern in currently circulating strains of emm4 Group A Streptococcus. Microb Genom 2018, 4(11).
Dib RW, Hachem R, Chaftari AM, Raad I: Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients. Mediterr J Hematol Infect Dis 2018, 10(1): e2018028.
Dib RW, Hachem RY, Chaftari AM, Ghaly F, Jiang Y, Raad I: Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies. BMC Infect Dis 2018, 18(1):656.
Economides MP, Amit M, Mahale PS, Hosry JJ, Jiang Y, Bharadwaj U, Sturgis EM, Torres HA: Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. Cancer 2018, 124(5):960-965.
El Haddad H, Chaftari AM, Hachem R, Chaftari P, Raad, II: Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin with Emphasis in Patients with Cancer. Clin Infect Dis 2018, 67(6):971-977.
Fernández-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, Kontoyiannis DP: Bronchoalveolar Lavage Fluid Cytology in Culture-Documented Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases: Analysis of 67 Episodes. J Clin Microbiol 2018, 56(10).
Folan SA, Marx KR, Tverdek FP, Raad I, Mulanovich VE, Tarrand JJ, Shelburne SA, Aitken SL: Clinical Outcomes Associated with Linezolid Resistance in Leukemia Patients with Linezolid-Resistant Staphylococcus epidermidis Bacteremia. Open Forum Infect Dis 2018, 5(7): ofy167.
Foolad F, Aitken SL, Chemaly RF: Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Rev Clin Pharmacol 2018, 11(10):931-941.
Galloway-Peña J, DebRoy S, Brumlow C, Li X, Tran TT, Horstmann N, Yao H, Chen K, Wang F, Pan BF et al: Hypervirulent group A Streptococcus emergence in an acaspular background is associated with marked remodeling of the bacterial cell surface. PLoS One 2018, 13(12): e0207897.
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC et al: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018, 359(6371):97-103.
Granwehr BP: In acute uncomplicated influenza, single dose baloxavir decreased time to symptom relief compared with placebo. Ann Intern Med 2018, 169(12): Jc63.
Hachem R, Kanj S, Hamerschlak N, Saad H, Assir FF, Mori N, Jiang Y, Ghaly F, Chaftari AM, Raad, II: International experience with minocycline, EDTA and ethanol lock for salvaging of central line associated bloodstream infections. Expert Rev Med Devices 2018, 15(6):461-466.
Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO: Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 2018, 24(2):353-358.
Holland TL, Raad I, Boucher HW, Anderson DJ, Cosgrove SE, Aycock PS, Baddley JW, Chaftari AM, Chow SC, Chu VH et al: Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. Jama 2018, 320(12):1249-1258.
Horstmann N, Tran CN, Brumlow C, DebRoy S, Yao H, Nogueras Gonzalez G, Makthal N, Kumaraswami M, Shelburne SA: Phosphatase activity of the control of virulence sensor kinase CovS is critical for the pathogenesis of group A streptococcus. PLoS Pathog 2018, 14(10): e1007354.
Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA: Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study. Clin Infect Dis 2018, 67(10):1635-1636.
Hosry J, Miranda RN, Samaniego F, Economides MP, Torres HA: Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 2018, 142(5):940-948.
Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, Ramondetta L, Parker SL, Suarez-Almazor ME, Ferrajoli A et al: Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 2018, 24(5):1094-1098.
Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP et al: Models to Predict Hepatitis B Virus Infection Among Patients with Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol 2018, 36(10):959-967.
Hwang JP, Torres HA: Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis 2018, 31(6):535-541.
Kasembeli MM, Bharadwaj U, Robinson P, Tweardy DJ: Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci 2018, 19(8).
Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ: Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget 2018, 9(58):31244-31252.
Leal SM, Jr., Popowitch EB, Levinson KJ, John TM, Lehman B, Rios MB, Gilligan PH, Miller MB: Quantitative Thresholds Enable Accurate Identification of Clostridium difficile Infection by the Luminex xTAG Gastrointestinal Pathogen Panel. J Clin Microbiol 2018, 56(6).
Li X, Arias CA, Aitken SL, Galloway Peña J, Panesso D, Chang M, Diaz L, Rios R, Numan Y, Ghaoui S et al: Clonal Emergence of Invasive Multidrug-Resistant Staphylococcus epidermidis Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses. Clin Infect Dis 2018, 67(3):398-406.
Lu H, Lok AS, Warneke CL, Ahmed S, Torres HA, Martinez F, Suarez-Almazor ME, Foreman JT, Ferrajoli A, Hwang JP: Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematol 2018, 5(10): e474-e478.
Magira EE, Jiang Y, Economides M, Tarrand J, Kontoyiannis DP: Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses 2018, 61(11):861-867.
Magira EE, Jiang Y, Kontoyiannis DP: Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species? Med Mycol 2018.
Mah A, Viola GM, Ariza Heredia E, Rezvani K, Kebriaei P, Bhatti MM, Han X, Shpall EJ, Mulanovich VE: Graft loss attributed to possible transfusion-transmitted ehrlichiosis following cord blood stem cell transplant. Transpl Infect Dis 2018, 20(4): e12899.
Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH et al: Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018, 38:262-279.
Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L et al: Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 2018, 379(15):1443-1451.
Mulanovich V, Kontoyiannis DP: Acute myeloid leukemia and the infectious diseases consultant. Leuk Lymphoma 2018, 59(6):1284-1291.
Raad, II, Chaftari AM, Dib RW, Graviss EA, Hachem R: Emerging outbreaks associated with conflict and failing healthcare systems in the Middle East. Infect Control Hosp Epidemiol 2018, 39(10):1230-1236.
Raad, II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R: Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018, 10(9):549-557.
Rajan A, Vela L, Zeng XL, Yu X, Shroyer N, Blutt SE, Poole NM, Carlin LG, Nataro JP, Estes MK et al: Novel Segment- and Host-Specific Patterns of Enteroaggregative Escherichia coli Adherence to Human Intestinal Enteroids. mBio 2018, 9(1).
Rice TW, Brock PA, Gonzalez C, Merriman KW, Shelal Z, Bazerbashi H, Granwehr BP: Routine HIV Screening in Cancer Patients in the Emergency Department. Acute Med 2018, 17(2):91-95.
Rolston KVI, Reitzel R, Vargas-Cruz N, Shelburne SA, Raad, II, Prince RA: In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer. Diagn Microbiol Infect Dis 2018, 91(4):351-353.
Sheshadri A, Shah DP, Godoy M, Erasmus JJ, Song J, Li L, Evans SE, Chemaly RF, Dickey BF, Ost DE: Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLoS One 2018, 13(5): e0197418.
Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP: Therapy of Mucormycosis. J Fungi (Basel) 2018, 4(3).
Tatara AM, Wurster S, Lockworth CR, Albert ND, Walsh TJ, Mikos AG, Eisenhoffer GT, Kontoyiannis DP: Immunosuppressed Adult Zebrafish Model of Mucormycosis. Antimicrob Agents Chemother 2018, 62(11).
Vakil E, Sheshadri A, Faiz SA, Shah DP, Zhu Y, Li L, Kmeid J, Azzi J, Balagani A, Bashoura L et al: Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. Transpl Infect Dis 2018, 20(6): e12994.
Vilar-Compte D, Shah DP, Vanichanan J, Cornejo-Juarez P, Garcia-Horton A, Volkow P, Chemaly RF: Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol 2018, 90(1):50-60.
Wilson Dib R, Chaftari AM, Hachem RY, Yuan Y, Dandachi D, Raad, II: Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy. Open Forum Infect Dis 2018, 5(10): ofy249.
Yalamanchili H, Dandachi D, Okhuysen PC: Use and Interpretation of Enteropathogen Multiplex Nucleic Acid Amplification Tests in Patients with Suspected Infectious Diarrhea. Gastroenterol Hepatol (N Y) 2018, 14(11):646-652.
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF et al: Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis 2018, 217(8):1247-1256.

2019

Abers MS, Lionakis MS, Kontoyiannis DP: Checkpoint Inhibition and Infectious Diseases: A Good Thing? Trends Mol Med 2019, 25(12):1080-1093.
Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CD: Germline Genetic Predisposition to Myeloid Neoplasia from GATA2 Gene Mutations: Lessons Learned from Two Cases. JCO Precis Oncol 2019, 3.
Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y: Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol 2019, 31(1):128-134.
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AM, Okhuysen PC, Jenq RR, Wang Y: Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019, 7(1):352.
Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, Jenq RR, Wang Y: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019, 7(1):242.
Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM et al: Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol 2019, 42(10):789-796.
Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N: Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2019, 60(13):3341-3342.
Alfayez M, Wang SA, Bannon SA, Kontoyiannis DP, Kornblau SM, Orange JS, Mace EM, DiNardo CD: Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. Leuk Lymphoma 2019, 60(8):2025-2033.
Benanti GE, Brown ART, Shigle TL, Tarrand JJ, Bhatti MM, McDaneld PM, Shelburne SA, Aitken SL: Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy. Antimicrob Agents Chemother 2019, 63(2).
Bharadwaj U, Eckols TK, Xu X, Kasembeli MM, Chen Y, Adachi M, Song Y, Mo Q, Lai SY, Tweardy DJ: Correction: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 2019, 10(16):1603.
Chaftari AM, Viola GM, Rosenblatt J, Hachem R, Raad I: Advances in the prevention and management of central-line-associated bloodstream infections: The role of chelator-based catheter locks. Infect Control Hosp Epidemiol 2019, 40(9):1036-1045.
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE et al: Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis 2019, 68(8):1420-1426.
Chemaly RF, Hill JA, Voigt S, Peggs KS: In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review. Antiviral Res 2019, 163:50-58.
Chikley A, Ben-Ami R, Kontoyiannis DP: Mucormycosis of the Central Nervous System. J Fungi (Basel) 2019, 5(3).
Chow NA, Toda M, Pennington AF, Anassi E, Atmar RL, Cox-Ganser JM, Da Silva J, Garcia B, Kontoyiannis DP, Ostrosky-Zeichner L et al: Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017. MMWR Morb Mortal Wkly Rep 2019, 68(21):469-473.
Cornely OA, Hoenigl M, Lass-Flörl C, Chen SC, Kontoyiannis DP, Morrissey CO, Thompson GR, 3rd: Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 2019, 62(9):716-729.
Dailey Garnes NJM, Ragoonanan D, Aboulhosn A: Adenovirus infection and disease in recipients of hematopoietic cell transplantation. Curr Opin Infect Dis 2019, 32(6):591-600.
De la Hoz A, Foolad F, Gallegos C, Kornblau S, Kontoyiannis DP: Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. Bone Marrow Transplant 2019, 54(5):749-751.
Debiane L, Reitzel R, Rosenblatt J, Gagea M, Chavez MA, Adachi R, Grosu HB, Sheshadri A, Hill LR, Raad I et al: A Design-Based Stereologic Method to Quantify the Tissue Changes Associated with a Novel Drug-Eluting Tracheobronchial Stent. Respiration 2019, 98(1):60-69.
DiPippo AJ, Kontoyiannis DP: Lack of Toxicity with Long-term Isavuconazole Use in Patients with Hematologic Malignancy. Clin Infect Dis 2019, 69(9):1624-1627.
DiPippo AJ, Rausch CR, Kontoyiannis DP: Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses 2019, 62(1):81-86.
El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L et al: The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis 2019, 219(6):898-907.
El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF: A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. Clin Infect Dis 2019, 69(1):167-178.
Fares J, Khalil M, Chaftari AM, Hachem R, Jiang Y, Kantarjian HM, Raad, II: Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients with Gram-Negative Bacteremia. Open Forum Infect Dis 2019, 6(10): ofz357.
Flores AR, Chase McNeil J, Shah B, Van Beneden C, Shelburne SA: Capsule-Negative emm Types Are an Increasing Cause of Pediatric Group A Streptococcal Infections at a Large Pediatric Hospital in Texas. J Pediatric Infect Dis Soc 2019, 8(3):244-250.
Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, Chemaly RF: Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2019, 68(10):1641-1649.
Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G et al: Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. Open Forum Infect Dis 2019, 6(5): ofz173.
Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S et al: HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 2019, 67(2):51-55.
Hachem R, Batista MV, Kanj SS, El Zein S, Haddad S, Jiang Y, Mori N, Vanderson R, Chaftari AM, Raad I: International Multicenter Experience in the Treatment Outcome of Invasive Aspergillosis in Immunocompromised Cancer Patients. Mediterr J Hematol Infect Dis 2019, 11(1): e2019003.
Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH: Oncologic Implications of Chronic Hepatitis C Virus Infection. J Oncol Pract 2019, 15(12):629-637.
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M et al: Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res 2019, 25(13):3996-4013.
Khawaja F, Batista MV, El Haddad L, Chemaly RF: Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr Opin Infect Dis 2019, 32(6):565-574.
Khawaja F, Chemaly RF: Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. Haematologica 2019, 104(7):1322-1331.
Kmeid J, Kulkarni PA, Batista MV, El Chaer F, Prayag A, Ariza-Heredia EJ, Mulanovich VE, Chemaly RF: Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006-2014. BMC Infect Dis 2019, 19(1):934.
Kontoyiannis DP: Is Candida auris here to stay? An interview with Dimitrios Kontoyiannis. Future Microbiol 2019, 14:1083-1085.
Kontoyiannis DP, Shah EC, Wurster S, Aitken SL, Graviss L, Raad, II, Chemaly RF: Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre- and Post-Hurricane Harvey. Open Forum Infect Dis 2019, 6(4): ofz138.
Kontoyiannis PD, Koons GL, Hicklen RS, Mikos AG, Kontoyiannis DP: Insect Bite-Associated Invasive Fungal Infections. Open Forum Infect Dis 2019, 6(10): ofz385.
Kuhlmann FM, Martin J, Hazen TH, Vickers TJ, Pashos M, Okhuysen PC, Gómez-Duarte OG, Cebelinski E, Boxrud D, Del Canto F et al: Conservation and global distribution of non-canonical antigens in Enterotoxigenic Escherichia coli. PLoS Negl Trop Dis 2019, 13(11): e0007825.
Lamoth F, Kontoyiannis DP: Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients. Antimicrob Agents Chemother 2019, 63(11).
Lewis RE, Kontoyiannis DP, Viale P, Sarpong EM: Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. Antimicrob Agents Chemother 2019, 63(12).
Lewis RE, Wurster S, Beyda ND, Albert ND, Kontoyiannis DP: Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. Diagn Microbiol Infect Dis 2019, 95(3):114861.
Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP: Corrigendum: Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients with Hematologic Malignancies: A Case-Control Study. Open Forum Infect Dis 2019, 6(11): ofz458.
Magira EE, Chemaly RF, Jiang Y, Tarrand J, Kontoyiannis DP: Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients with Hematologic Malignancies: A Case-Control Study. Open Forum Infect Dis 2019, 6(7): ofz247.
Malek AE, Fares JE, Raad, II, Ericsson C: Pasteurella multocida vertebral osteomyelitis, myositis and epidural abscess in a diabetic cirrhotic patient. IDCases 2019, 18: e00630.
Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME et al: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019, 25(2):369-381.
Mason MJ, McDaneld PM, Musick WL, Kontoyiannis DP: Serum Levels of Crushed Posaconazole Delayed-Release Tablets. Antimicrob Agents Chemother 2019, 63(5).
Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA et al: A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis 2019, 68(2):196-203.
Muñoz NM, Minhaj AA, Dupuis CJ, Ensor JE, Golardi N, Jaso JM, Dixon KA, Figueira TA, Galloway-Peña JR, Hill L et al: What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis? Clin Orthop Relat Res 2019, 477(10):2367-2377.
Narula N, Lillemoe HA, Caudle AS, Chemaly RF, Anderson JJ, Segal C, Porter CA, Swisher SG, Levenback CF, Aloia TA: Postoperative Urinary Tract Infection Quality Assessment and Improvement: The S.T.O.P. UTI Program and Its Impact on Hospital wide CAUTI Rates. Jt Comm J Qual Patient Saf 2019, 45(10):686-693.
Pergam SA, Englund JA, Kamboj M, Gans HA, Young JH, Hill JA, Savani B, Chemaly RF, Dadwal SS, Storek J et al: Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 2019, 25(11): e321-e330.
Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Sciumè M et al: Rhodotorula infection in haematological patient: Risk factors and outcome. Mycoses 2019, 62(3):223-229.
Rolston KVI, Jamal M, Nesher L, Raad I, Rice SA, Rybak MJ, Prince RA: Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients. J Glob Antimicrob Resist 2019, 17:16-18.
Rosenblatt J, Vargas-Cruz N, Reitzel RA, Raad, II: Assessment of the Potential for Inducing Resistance in Multidrug-Resistant Organisms from Exposure to Minocycline, Rifampin, and Chlorhexidine Used to Treat Intravascular Devices. Antimicrob Agents Chemother 2019, 63(5).
Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M et al: Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 2019, 25(4):800-809.
Sheshadri A, Godoy M, Erasmus JJ, Gruschkus S, Hasan A, Evans SE, Barreda-Garcia J, Chemaly RF, Dickey B, Ost D: Progression of the Radiologic Severity Index is associated with increased mortality and healthcare resource utilisation in acute leukaemia patients with pneumonia. BMJ Open Respir Res 2019, 6(1): e000471.
Sheshadri A, Karimipour M, Vakil E, Bashoura L, Godoy M, Arain MH, Evans SE, Dickey BF, Ost DE, Chemaly RF et al: Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection. Transpl Infect Dis 2019, 21(4): e13105.
Stanzani M, Vianelli N, Cavo M, Kontoyiannis DP, Lewis RE: Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. J Infect 2019, 78(6):484-490.
Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A: Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2019, 60(2):535-537.
Szvalb AD, El Haddad H, Rolston KV, Sabir SH, Jiang Y, Raad, II, Viola GM: Risk factors for recurrent percutaneous nephrostomy catheter-related infections. Infection 2019, 47(2):239-245.
Szvalb AD, Kontoyiannis DP: Acute acalculous cholecystitis due to Fusarium species and review of the literature on fungal cholecystitis. Mycoses 2019, 62(9):847-853.
Szvalb AD, Rolston KV, Mori N, Tarrand JJ, Mulanovich VE: Infections with the agent of 'kennel cough' in patients with cancer. J Infect 2019, 78(1):48-53.
Tahtouh R, Wardi L, Sarkis R, Hachem R, Raad I, El Zein N, Hilal G: Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines. Cell Mol Biol (Noisy-le-grand) 2019, 65(7):26-33.
Taremi M, Artau A, Foolad F, Berlin S, White C, Jiang Y, Raad I, Adachi J: Safety, Efficacy, and Clinical Impact of Penicillin Skin Testing in Immunocompromised Cancer Patients. J Allergy Clin Immunol Pract 2019, 7(7):2185-2191.e2181.
Tatara AM, Watson E, Albert ND, Kontoyiannis PD, Kontoyiannis DP, Mikos AG: A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies. J Biomed Mater Res A 2019, 107(9):1867-1874.
Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A et al: Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol 2019, 114(2):250-257.
Torres HA, Pundhir P, Mallet V: Hepatitis C Virus Infection in Patients with Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. Gastroenterology 2019, 157(4):909-916.
Tran TT, Mishra NN, Seepersaud R, Diaz L, Rios R, Dinh AQ, Garcia-de-la-Maria C, Rybak MJ, Miro JM, Shelburne SA et al: Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother 2019, 63(2).
Vargas-Cruz N, Reitzel RA, Rosenblatt J, Chaftari AM, Wilson Dib R, Hachem R, Kontoyiannis DP, Raad, II: Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm. Antimicrob Agents Chemother 2019, 63(7).
Vargas-Cruz N, Rosenblatt J, Reitzel RA, Chaftari AM, Hachem R, Raad I: Pilot Ex Vivo and In Vitro Evaluation of a Novel Foley Catheter with Antimicrobial Periurethral Irrigation for Prevention of Extraluminal Biofilm Colonization Leading to Catheter-Associated Urinary Tract Infections (CAUTIs). Biomed Res Int 2019, 2019:2869039.
Viola GM, Rolston KV, Butler C, Selber J, Reece G, Clemens M, Villa M, Raad, II, Baumann D: Evaluation of Current Perioperative Antimicrobial Regimens for the Prevention of Surgical Site Infections in Breast Implant-based Reconstructive Surgeries. Plast Reconstr Surg Glob Open 2019, 7(7): e2342.
Walsh TJ, Hospenthal DR, Petraitis V, Kontoyiannis DP: Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. J Fungi (Basel) 2019, 5(3).
Wang EW, Bhatti M, Cantu S, Okhuysen PC: Diagnosis of Yersinia enterocolitica Infection in Cancer Patients with Diarrhea in the Era of Molecular Diagnostics for Gastrointestinal Infections. Open Forum Infect Dis 2019, 6(4): ofz116.
Wang Q, Kontoyiannis DP, Li R, Chen W, Bu D, Liu W: A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. J Clin Microbiol 2019, 57(9).
Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad, II, Kontoyiannis DP: Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother 2019, 74(7):1904-1910.
Wurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, Kontoyiannis DP: Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. mBio 2019, 10(3).
Wurster S, Lewis RE, Albert ND, Kontoyiannis DP: Preexposure to Isavuconazole Increases the Virulence of Mucorales but Not Aspergillus fumigatus in a Drosophila melanogaster Infection Model. Antimicrob Agents Chemother 2019, 63(2).
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF et al: Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated with Viral Clearance in Hematopoietic Cell Transplantation Adults. Front Immunol 2019, 10:706.
Zhang H, Tan J, Kontoyiannis DP, Zhou Y, Liu W, Zhu P, Shi X, Wan Z, Li R, Liu W: Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagn Microbiol Infect Dis 2019, 95(2):166-170.
Zhang X, Browman G, Siu W, Basen-Engquist KM, Hanash SM, Hoffman KL, Okhuysen PC, Scheet P, Petrosino JF, Kopetz S et al: The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer. BMC Cancer 2019, 19(1):1233.

2020

Abu-Sbeih H, Ali FS, Chen E, Mallepally N, Luo W, Lu Y, Foo WC, Qiao W, Okhuysen PC, Adachi JA et al: Neutropenic Enterocolitis: Clinical Features and Outcomes. Dis Colon Rectum 2020, 63(3):381-388.
Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D et al: Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis 2020, 22(5): e13395.
Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ et al: A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist 2020, 25(6): e936-e945.
Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T et al: Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Ann Intern Med 2020, 172(5):306-316.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D et al: Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant 2020, 26(12):2181-2189.
Alvarez-Cardona JJ, Whited LK, Chemaly RF: Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. Future Microbiol 2020, 15:389-400.
Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA: Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infect Dis 2020, 7(12): ofaa509.
Anastasopoulou A, DiPippo AJ, Kontoyiannis DP: Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses 2020, 63(8):787-793.
Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Kaseb A, Torres HA: Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma. Hepatology 2020, 72(2):775-777.
Angelidakis G, Mahale P, Jonasch E, Jiang Y, Torres HA: Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. Semin Oncol 2020, 47(2-3):165-167.
Arora S, Li X, Hillhouse A, Konganti K, Little SV, Lawhon SD, Threadgill D, Shelburne S, Hook M: Staphylococcus epidermidis MSCRAMM SesJ Is Encoded in Composite Islands. mBio 2020, 11(1).
Bajaj N, Granwehr BP, Hanna EY, Chambers MS: Salivary detection of SARS-CoV-2 (COVID-19) and implications for oral health-care providers. Head Neck 2020, 42(7):1543-1547.
Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ: Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Pharmacol Rev 2020, 72(2):486-526.
Cabrera NL, Malek AE, Shelburne S, Taremi M, Awadh H, Francisco D, Robins A, Jabbour E, Chemaly RF: Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy. Infection 2020, 48(3):477-481.
Chakravarti D, Hu B, Mao X, Rashid A, Li J, Li J, Liao WT, Whitley EM, Dey P, Hou P et al: Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun 2020, 11(1):4766.
Chemaly RF, Dadwal SS, Bergeron A, Ljungman P, Kim YJ, Cheng GS, Pipavath SN, Limaye AP, Blanchard E, Winston DJ et al: A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clin Infect Dis 2020, 71(11):2777-2786.
Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, Avery RK, Hari P, Peggs KS, Kumar D et al: Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin Infect Dis 2020, 71(9):2365-2374.
Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK et al: Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist 2020, 25(9): e1426-e1427.
Dib RW, Khalil M, Fares J, Hachem RY, Jiang Y, Dandachi D, Chaftari AM, Raad, II: Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours. J Hosp Infect 2020, 104(3):358-364.
Dipippo AJ, Kontoyiannis DP: Azole-Associated Pseudohyperaldosteronism: A Class Effect or Azole-Specific? Clin Infect Dis 2020, 71(2):467-468.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH et al: Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020, 71(6):1367-1376.
El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R et al: Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol 2020, 92(1):86-95.
ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, Mohmed S, Alshaibani A, Cesaro S, Abd El-Aziz N et al: The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020.
Fernández-Cruz A, Lewis RE, Kontoyiannis DP: How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. Clin Infect Dis 2020, 71(3):685-692.
Flores AR, Shelburne SA: Toward an Understanding of Group a Streptococcal Transmission Dynamics Using National-level Surveillance. Clin Infect Dis 2020, 70(7):1482-1483.
Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ: Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma 2020, 61(10):2488-2491.
Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, Pulsoni A, Torres HA, Peveling-Oberhag J, Rossotti R et al: Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia 2020, 34(5):1462-1466.
Fuentes S, Hahn M, Chilcote K, Chemaly RF, Shah DP, Ye X, Avadhanula V, Piedra PA, Golding H, Khurana S: Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans. J Infect Dis 2020, 221(4):636-646.
Galloway-Peña JR, Kontoyiannis DP: The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions. PLoS Pathog 2020, 16(4): e1008353.
Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW et al: Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis 2020, 71(1):63-71.
Garcia-Vidal C, Lewis RE, Kontoyiannis DP: Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. J Antimicrob Chemother 2020, 75(11):3096-3098.
Gómez-Sandoval JN, Okhuysen P, Mondragón-Flores R, Escalona-Montaño AR, Aguirre-García MM: Cellular Identification and In Silico Characterization of Protein Phosphatase 2C (PP2C) of Cryptosporidium parvum. Acta Parasitol 2020, 65(3):704-715.
Hanage WP, Shelburne SA: Streptococcus pyogenes With Reduced Susceptibility to β-Lactams: How Big an Alarm Bell? Clin Infect Dis 2020, 71(1):205-206.
Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA: Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus-infected patients. Hematol Oncol 2020, 38(3):301-308.
John TM, Malek AE, Mulanovich VE, Adachi JA, Raad, II, Hamilton AR, Shpall EJ, Rezvani K, Aitken SL, Jain N et al: Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. Mayo Clin Proc 2020, 95(9):2038 2040.
Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA et al: Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis 2020, 222(Suppl 3): S175-s198.
Khalil M, Karimzad K, Durand JB, Malek AE, Raad, II, Viola GM: Prevention of Cardiac Implantable Electronic Device-Related Infection in Patients with Cancer: The Role of a Comprehensive Prophylactic Bundle Approach That Includes the Antimicrobial Mesh. Open Forum Infect Dis 2020, 7(11): ofaa433.
Kim J, Greenberg DE, Pifer R, Jiang S, Xiao G, Shelburne SA, Koh A, Xie Y, Zhan X: VAMPr: VAriant Mapping and Prediction of antibiotic resistance via explainable features and machine learning. PLoS Comput Biol 2020, 16(1): e1007511.
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L et al: Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid from Leukemia Patients with Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 2020, 11:590494.
Koehler P, Denis B, Denning DW, Gangneux JP, Hoenigl M, Kontoyiannis DP, Krause R, Lagrou K, Lass-Flörl C, Maertens J et al: European confederation of medical mycology expert consult-An ECMM excellence center initiative. Mycoses 2020, 63(6):566-572.
Lewis RE, Kontoyiannis DP: Infectious disease consultation for candidaemia. Lancet Infect Dis 2020, 20(2):164.
Lewis RE, Kontoyiannis DP: Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. Clin Infect Dis 2020, 71(7):1802-1803.
Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K et al: A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis 2020, 70(8):1525-1533.
Malek A, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich V et al: Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis 2020.
Malek AE, Granwehr BP, Kontoyiannis DP: Doxycycline as a potential partner of COVID-19 therapies. IDCases 2020, 21: e00864.
Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J et al: Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. Mediterr J Hematol Infect Dis 2020, 12(1): e2020044.
Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad, II, Torres HA: Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-Cancer Therapy Including Ibrutinib. Clin Lymphoma Myeloma Leuk 2020, 20(3): e124-e127.
Malek AE, Raad, II: Preventing catheter-related infections in cancer patients: a review of current strategies. Expert Rev Anti Infect Ther 2020, 18(6):531-538.
Malek AE, Raad, II, Jabbour E: Cancer and COVID-19. Lancet 2020, 396(10257):1066-1067.
Malek AE, Skaff Y, Mulanovich VE: Correction to: Voriconazole-induced periostitis in stem cell transplant patient. Infection 2020, 48(5):811.
Malek AE, Skaff Y, Mulanovich VE: Voriconazole-induced periostitis in stem cell transplant patient. Infection 2020, 48(5):809-810.
Malek AE, Viola GM, Seiler GT, Szvalb AD: Disseminated Nocardia farcinica infection in immunocompromised patient. Infection 2020, 48(3):487-488.
Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP et al: SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 2020, 61(11):2763-2766.
Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, Bergeron A, Shoham S, Ljungman P, Waghmare A et al: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. Clin Infect Dis 2020, 71(11):2787-2795.
Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, Yeh WW, Leavitt RY, Badshah CS: Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant 2020, 20(6):1703-1711.
Minus MB, Wang H, Munoz JO, Stevens AM, Mangubat-Medina AE, Krueger MJ, Liu W, Kasembeli MM, Cooper JC, Kolosov MI et al: Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors. Org Biomol Chem 2020, 18(17):3288-3296.
Mitra A, Grossman Biegert GW, Delgado AY, Karpinets TV, Solley TN, Mezzari MP, Yoshida-Court K, Petrosino JF, Mikkelson MD, Lin L et al: Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys 2020, 107(1):163-171.
Pappas PG, Boulware DR, Kontoyiannis DP, Miceli MH, Ostrosky-Zeichner L, Spec A, Thompson GR, Chen S, Perfect JR: Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. Med Mycol 2020, 58(5):569-578.
Pritchard H, Jandhyala D, Hosry J, Angelidakis G, Torres HA: Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals-A prospective study. JGH Open 2020, 4(3):541-544.
Puerta-Alcalde P, Champlin R, Kontoyiannis DP: How I transplant a patient with a history of invasive fungal disease. Blood 2020.
Rajan A, Robertson MJ, Carter HE, Poole NM, Clark JR, Green SI, Criss ZK, Zhao B, Karandikar U, Xing Y et al: Enteroaggregative E. coli Adherence to Human Heparan Sulfate Proteoglycans Drives Segment and Host Specific Responses to Infection. PLoS Pathog 2020, 16(9): e1008851.
Reitzel RA, Rosenblatt J, Gerges BZ, Jarjour A, Fernández-Cruz A, Raad, II: The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review. JAC Antimicrob Resist 2020, 2(1): dlaa002.
Reitzel RA, Rosenblatt J, Gerges BZ, Vargas-Cruz N, Raad, II: Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective In Vitro for Eradication of Candida auris Biofilms. Antimicrob Agents Chemother 2020, 64(4).
Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jenq RR, Shelburne S, Shah DP, Chambers MS, Hanna EY et al: Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer 2020, 126(23):5124-5136.
Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP, Galloway-Peña JR: Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. mSphere 2020, 5(2).
Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA: Activity of Cefiderocol and Comparators against Isolates from Cancer Patients. Antimicrob Agents Chemother 2020, 64(5).
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B et al: Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun 2020, 11(1):661.
Shelburne SA, Dib RW, Endres BT, Reitzel R, Li X, Kalia A, Sahasrabhojane P, Chaftari AM, Hachem R, Vargas-Cruz NS et al: Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect 2020, 26(5): 646.e641-646.e648.
Shigle TL, Handy VW, Chemaly RF: Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. Ther Adv Hematol 2020, 11:2040620720937150.
Spallone A, Hicklen RS, Kontoyiannis DP: Invasive Fungal Infections at Presentation of Untreated Hematologic Malignancies: Rare and Elusive. Open Forum Infect Dis 2020, 7(7): ofaa247.
Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F et al: Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 2020.
Szvalb AD, Malek AE, Jiang Y, Bhatti MM, Wurster S, Kontoyiannis DP: Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR. J Infect 2020, 81(3):443-451.
Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, El Boghdadly Z, Kamboj M, Papanicolaou GA, Pergam SA, Shahid Z: Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant 2020, 26(11):1983-1994.
Wurster S, Robinson P, Albert ND, Tarrand JJ, Goff M, Swamydas M, Lim JK, Lionakis MS, Kontoyiannis DP: Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy with Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model. J Infect Dis 2020, 222(6):989-994.
Wurster S, Sass G, Albert ND, Nazik H, Déziel E, Stevens DA, Kontoyiannis DP: Live imaging and quantitative analysis of Aspergillus fumigatus growth and morphology during inter-microbial interaction with Pseudomonas aeruginosa. Virulence 2020, 11(1):1329-1336.
Wurster S, Tatara AM, Albert ND, Ibrahim AS, Heitman J, Lee SC, Shetty AC, McCracken C, Graf KT, Mikos AG et al: Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds. mBio 2020, 11(3).
Yang X, Shi X, Chen W, Zhou Y, Lionakis MS, Kontoyiannis DP, Liu W: First report of kerion (tinea capitis) caused by combined Trichophyton mentagrophytes and Microsporum canis. Med Mycol Case Rep 2020, 29:5-7.
Ye X, Cabral de Rezende W, Iwuchukwu OP, Avadhanula V, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF, Piedra PA: Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Vaccines (Basel) 2020, 8(2).
Yibirin M, Pritchard H, Torres HA: False-positive Trypanosoma cruzi serology in a cancer patient receiving intravenous immunoglobulin. Diagn Microbiol Infect Dis 2020, 97(4):115057.
Zhang L, Chen Z, Wang Y, Tweardy DJ, Mitch WE: Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40. Am J Physiol Endocrinol Metab 2020, 318(5): E625-e635.
Zhang L, Wang Y, Dong Y, Chen Z, Eckols TK, Kasembeli MM, Tweardy DJ, Mitch WE: Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease. Am J Physiol Renal Physiol 2020, 319(1): F84-f92.

2021

Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Peña JR: Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated with Stenotrophomonas maltophilia Infection in Patients with Acute Myeloid Leukemia Receiving Chemotherapy. Clin Infect Dis 2021, 72(9):1507-1513.
Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y: Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol 2021, 93(6):3786-3794.
Ariza-Heredia EJ, Frenzel E, Cantu S, Carlson M, Thomas G, Khawaja F, Raad, II, Chemaly RF: Surveillance and identification of clusters of healthcare workers with coronavirus disease 2019 (COVID-19): Multidimensional interventions at a comprehensive cancer center. Infect Control Hosp Epidemiol 2021, 42(7):797-802.
Awadh H, Chaftari AM, Khalil M, Fares J, Jiang Y, Deeba R, Ali S, Hachem R, Raad, II: Management of enterococcal central line-associated bloodstream infections in patients with cancer. BMC Infect Dis 2021, 21(1):643.
Axell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad, II, Kontoyiannis DP: Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. J Fungi (Basel) 2021, 7(3).
Ben-Ami R, Kontoyiannis DP: Resistance to Antifungal Drugs. Infect Dis Clin North Am 2021, 35(2):279-311.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K et al: Isavuconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis 2021, 72(10):1755-1763.
Carpenter PA, Papanicolaou G, Chemaly RF, Boeckh M, Savani BN: American Society for Transplantation and Cellular Therapy Infectious Disease Guidelines: Preface to the Series. Transplant Cell Ther 2021, 27(2):103-104.
Casadevall A, Kontoyiannis DP, Robert V: Environmental Candida auris and the Global Warming Emergence Hypothesis. mBio 2021, 12(2).
Chamilos G, Lionakis MS, Kontoyiannis DP: Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)? Clin Infect Dis 2021, 72(2):351-356.
Chemaly RF: The ever-growing world of infections in immunocompromised patients: major headways with numerous shortcomings. Clin Microbiol Infect 2021.
Chemaly RF, Marty FM, Wolfe CR, Lawrence SJ, Dadwal S, Soave R, Farthing J, Hawley S, Montanez P, Hwang J et al: DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. Clin Infect Dis 2021, 73(3): e773-e781.
Colombo AL, Agnelli C, Kontoyiannis DP: Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients. J Antimicrob Chemother 2021, 76(3):543-546.
Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, Fisher BT, Slavin MA, Kontoyiannis DP: American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transplant Cell Ther 2021, 27(3):201-211.
DebRoy S, Aliaga-Tobar V, Galvez G, Arora S, Liang X, Horstmann N, Maracaja-Coutinho V, Latorre M, Hook M, Flores AR et al: Genome-wide analysis of in vivo CcpA binding with and without its key co-factor HPr in the major human pathogen group A Streptococcus. Mol Microbiol 2021, 115(6):1207-1228.
DebRoy S, Sanson M, Shah B, Regmi S, Vega LA, Odo C, Sahasrabhojane P, McGeer A, Tyrrell GJ, Fittipaldi N et al: Population Genomics of emm4 Group A Streptococcus Reveals Progressive Replacement with a Hypervirulent Clone in North America. mSystems 2021: e0049521.
El Haddad L, Hanson BM, Arias CA, Ghantoji SS, Harb CP, Stibich M, Chemaly RF: Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms. Clin Infect Dis 2021.
Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, Kontoyiannis DP, Lamoth F: COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? Clin Microbiol Infect 2021.
Gans H, Chemaly RF: Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program. BMC Infect Dis 2021, 21(1):46.
Gerges BZ, Rosenblatt J, Truong YL, Reitzel RA, Hachem R, Raad, II: Enhanced Biofilm Eradication and Reduced Cytotoxicity of a Novel Polygalacturonic and Caprylic Acid Wound Ointment Compared with Common Antiseptic Ointments. Biomed Res Int 2021, 2021:2710484.
Gerges BZ, Rosenblatt J, Truong YL, Reitzel RA, Raad I: Review of allergic reactions from use of chlorhexidine on medical products in clinical settings over 40 years: Risks and mitigations. Infect Control Hosp Epidemiol 2021:1-15.
Grable C, Yusuf S, Song J, Viola GM, Ulhaq O, Banchs J, Jensen CT, Goel H, Hassan S: Characteristics of infective endocarditis in a cancer population. Open Heart 2021, 8(2).
Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A et al: High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated with Improved Survival in COVID-19 Patients. Front Immunol 2021, 12:675679.
Gudiol C, Lewis RE, Strati P, Kontoyiannis DP: Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol 2021, 8(3): e216-e228.
Hachem R, Parikh UM, Reitzel R, Rosenblatt J, Kaul A, Vargas-Cruz N, Hill L, Moore L, Meyer J, Chaftari AM et al: Novel antimicrobial ointment for infected wound healing in an in vitro and in vivo porcine model. Wound Repair Regen 2021.
Handley G, Hasbun R, Okhuysen P: Human herpesvirus 6 and central nervous system disease in oncology patients: A retrospective case series and literature review. J Clin Virol 2021, 136:104740.
Husni R, Chrabieh R, Dib RW, Vazquez J, Guimaraes T, Fernández A, Khoury R, Asmar L, Khazen G, Samaha N et al: Timing for Step-Down Therapy of Candidemia in Non-Neutropenic Patients: An International Multi-Center Study. Mediterr J Hematol Infect Dis 2021, 13(1): e2021031.
John TM, Kontoyiannis DP: Do Not Forget Daptomycin as a Cause of Eosinophilic Pneumonia! Chest 2021, 159(4):1687-1688.
John TM, Shrestha NK, Procop GW, Grove D, Leal SM, Jr., Jacob CN, Butler R, Dweik R: Diagnosis of Clostridioides difficile infection by analysis of volatile organic compounds in breath, plasma, and stool: A cross-sectional proof-of-concept study. PLoS One 2021, 16(8): e0256259.
Karri PV, Torres CA, Dailey Garnes NJ, Ronen S, Khawaja F, Bhatti MM, Hosing C, Patel AB: Disseminated atypical mycobacterial infection in an allogeneic stem cell transplant recipient. Dermatol Online J 2021, 27(6).
Kaseb AO, Mohamed YI, Malek AE, Raad, II, Altameemi L, Li D, Kaseb OA, Kaseb SA, Selim A, Ma Q: The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens 2021, 10(3).
Kasembeli MM, Singhmar P, Ma J, Edralin J, Tang Y, Adams C, 3rd, Heijnen CJ, Kavelaars A, Tweardy DJ: TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain. Biochem Pharmacol 2021, 192:114688.
Kondapi DS, Ramani S, Estes MK, Atmar RL, Okhuysen PC: Norovirus in Cancer Patients: A Review. Open Forum Infect Dis 2021, 8(6): ofab126.
Kong R, Bharadwaj U, Eckols TK, Kolosov M, Wu H, Cruz-Pavlovich FJS, Shaw A, Ifelayo OI, Zhao H, Kasembeli MM et al: Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility. Pharmacol Res 2021, 169:105637.
Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotanidou A, Hagberg CA et al: Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect 2021, 83(1):1-16.
Korompoki E, Gavriatopoulou M, Kontoyiannis DP: COVID-19 Vaccines in Patients with Cancer-A Welcome Addition, but There Is Need for Optimization. JAMA Oncol 2021, 7(8):1113-1114.
Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP: Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). J Infect Dis 2021.
Lass-Flörl C, Dietl AM, Kontoyiannis DP, Brock M: Aspergillus terreus Species Complex. Clin Microbiol Rev 2021: e0031120.
Lockhart SR, Bialek R, Kibbler CC, Cuenca-Estrella M, Jensen HE, Kontoyiannis DP: Molecular Techniques for Genus and Species Determination of Fungi from Fresh and Paraffin-Embedded Formalin-Fixed Tissue in the Revised EORTC/MSGERC Definitions of Invasive Fungal Infection. Clin Infect Dis 2021, 72(Suppl 2): S109-s113.
Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M et al: Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients with Superimposed Gastrointestinal Infections. Am J Clin Oncol 2021, 44(8):402-408.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I et al: Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021, 397(10273):499-509.
Malek AE, Adachi JA, Mulanovich VE, Sassine J, Raad, II, McConn K, Seiler GT, Dhal U, Khawaja F, Chemaly RF: Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients. Transpl Infect Dis 2021: e13606.
Malek AE, Granwehr BP: Doxycycline as an Alternative to Azithromycin in Elderly Patients. Int J Antimicrob Agents 2021, 57(1):106168.
Malek AE, Kontoyiannis DP: Superficial Thrombophlebitis from Intravenous Pentamidine in Hematopoietic Cell Transplantation Recipient. Mayo Clin Proc 2021, 96(1):257-258.
Marcelin JR, Cortés-Penfield N, Del Rio C, Desai A, Echenique I, Granwehr B, Lawal F, Kuriakose K, Lee DH, Malinis M et al: How the Field of Infectious Diseases Can Leverage Digital Strategy and Social Media Use During a Pandemic. Open Forum Infect Dis 2021, 8(2): ofab027.
Mulroney CM, Bilal Abid M, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E et al: Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Br J Haematol 2021, 194(1):145-157.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM et al: Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 2021, 39(24):2710-2719.
Olvera A, Carter H, Rajan A, Carlin LG, Yu X, Zeng XL, Shelburne S, Bhatti M, Blutt SE, Shroyer NF et al: Enteropathogenic Escherichia coli Infection in Cancer and Immunosuppressed Patients. Clin Infect Dis 2021, 72(10): e620-e629.
Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C: How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect 2021, 27(7):981-986.
Pérez-Jacoiste Asín MA, López-Medrano F, Fernández-Ruiz M, Silva JT, San Juan R, Kontoyiannis DP, Aguado JM: Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis. Am J Transplant 2021, 21(2):703-716.
Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang L, Miller E, Torres HA: Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. J Viral Hepat 2021, 28(5):844-848.
Pundhir P, Roach LR, Bartek JR, Trask RP, Yibirin M, Guevara EY, Granwehr BP, Swalwell CR, Torres HA: Nursing practice is associated with high risk for hepatitis C virus infection. Clin Microbiol Infect 2021.
Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K et al: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents, and young adults with cancer. Nat Rev Clin Oncol 2021, 18(7):435-453.
Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P et al: Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 2021, 11:625707.
Sanson MA, Vega LA, Shah B, Regmi S, Cubria MB, Horstmann N, Shelburne SA, 3rd, Flores AR: The LiaFSR transcriptome reveals an interconnected regulatory network in group A Streptococcus. Infect Immun 2021: Iai0021521.
Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken S, Jiang Y, Champlin R, Shpall E, Rezvani K et al: Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis 2021.
Sassine J, Kontoyiannis DP: A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion. Am J Med 2021, 134(7):860-862.
Satlin MJ, Weissman SJ, Carpenter PA, Seo SK, Shelburne SA: American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation. Transplant Cell Ther 2021, 27(2):108-114.
Shah S, Shelburne S: Skin and Soft Tissue Infections in Non-Human Immunodeficiency Virus Immunocompromised Hosts. Infect Dis Clin North Am 2021, 35(1):199-217.
Shropshire WC, Aitken SL, Pifer R, Kim J, Bhatti MM, Li X, Kalia A, Galloway-Peña J, Sahasrabhojane P, Arias CA et al: IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. J Antimicrob Chemother 2021, 76(2):385-395.
Simmons SE, Carrion R, Alfson KJ, Staples HM, Jinadatha C, Jarvis WR, Sampathkumar P, Chemaly RF, Khawaja F, Povroznik M et al: Deactivation of SARS-CoV-2 with pulsed-xenon ultraviolet light: Implications for environmental COVID-19 control. Infect Control Hosp Epidemiol 2021, 42(2):127-130.
Spallone A, Schwartz IS: Emerging Fungal Infections. Infect Dis Clin North Am 2021, 35(2):261-277.
Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S et al: Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer 2021, 29(1):97 105.
Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, Holland SM, Kontoyiannis DP: Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: An underappreciated association. Mycoses 2021, 64(6):576-582.
Wurster S, Lyos S, Albert ND, Kontoyiannis DP: Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. Med Mycol 2021, 59(1):102-105.
Wurster S, Ruiz OE, Samms KM, Tatara AM, Albert ND, Kahan PH, Nguyen AT, Mikos AG, Kontoyiannis DP, Eisenhoffer GT: EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Cell Rep 2021, 34(12):108896.
Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Henke DM, Patel KD, Piedra FA, Angelo LS, Shah DP et al: Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. Viruses 2021, 13(6).

Why This Program

In addition to gaining unparalleled education and training experience, MD Anderson trainees have access to exceptional resources and benefits to help them build meaningful careers and lead fulfilling lives.

Institutional benefits and support

GME trainees’ salary stipends are updated every year based on the ACGME’s recommendations, and because our trainees are considered workforce members, they also enjoy MD Anderson’s employee benefits, including health insurance, retirement planning, disability insurance and six weeks of parental leave.

Our GME House Staff Senate offers trainees the opportunity to experience a leadership role in a medical field career, and the institution’s Academic Mentoring Council provides avenues to secure tailored academic mentoring from faculty. Our GME trainees benefit from the extensive support offered to our research trainees, too; they are invited to participate in grant application workshops, apply for pilot grants to support their research ideas and receive monetary awards for securing extramural grant funding.

Trainee wellness is also of utmost importance at MD Anderson.

Our trainees have access to MD Anderson’s employee networks, fitness center and other wellness resources provided by the institution. Additionally, our Graduate Medical Education Committee (GMEC), which provides oversight of our accredited programs, regularly assess our trainees’ needs and implements various initiatives, such as providing free call meals and discounted parking to GME House Staff, to address those gaps. The committee even has a subcommittee entirely dedicated to supporting the wellness of our trainees.

Our efforts to ensure a welcoming and supportive education and training experience have been commended nationally. In 2023, the Office of Graduate Medical Education received the DeWitt C. Baldwin, Jr. Award, a prestigious national award that recognizes our institution for its respectful and supportive environment for delivering medical education and patient care.

Beyond MD Anderson

MD Anderson’s location has many benefits, too. Our main campus is nestled inside the Texas Medical Center, the world’s largest medical center which boasts about 10 million patient encounters each year. Many of our faculty are involved in interorganizational research collaborations, both within the TMC and across the nation, exposing trainees to groundbreaking advancements in medical care in real time.

Most importantly, the city of Houston is a great place to call home and raise a family. We are one of the most culturally diverse cities in the nation. More than 145 different languages are spoken across the city, placing us behind only New York and Los Angeles. In fact, about 30% of the city’s population speaks a language other than English at home. And, paychecks here stretch farther than most U.S. metro areas, thanks to our low cost of living.

Visit our Why Houston page to learn more about our city’s affordable housing, fine dining, entertainment scene, nationally renowned museums and other great attributes.